Thompson A M, Bridges A J, Fry D W, Kraker A J, Denny W A
Cancer Research Laboratory, University of Auckland School of Medicine, New Zealand.
J Med Chem. 1995 Sep 15;38(19):3780-8. doi: 10.1021/jm00019a007.
The synthesis of 7-aminopyrido[4,3-d]pyrimidines bearing aromatic side chains at the 4-position is reported. These compounds are shown to be a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Structure-activity relationships (SARs) for substitution in both 4-(phenylamino)- and 4-[(phenylmethyl)amino] side chains were determined, using a series of substituents (NO2, Br, CF3, OMe, NH2, and NMe2) selected primarily for their wide range of electronic properties. In the phenylamino series, 3-substituted derivatives were more potent than the corresponding 2- and 4-substituted analogues. For the 3-substituted compounds, activity was favored by electron withdrawal, in a relationship which could be quantified, with the 3-Br being the most potent compound (IC50 = 0.01 microM compared with IC50 = 0.34 microM for the unsubstituted side chain derivative). No such correlation was apparent for the 2- or 4-substituent, although Br was still the best substituent. In contrast, in the 4-[(phenylmethyl)amino] series, substitution of the side chain was not beneficial. For the 4-(phenylamino) series, the substituent SARs are broadly similar to that found previously for 4-(phenylamino)quinazolines. These results suggest that side chain SARs may be broadly invariant over a range of different chromophores, with the side chain of choice for optimization of EGFR inhibitory activity being 4-[(3-bromophenyl)amino].
报道了在4-位带有芳香族侧链的7-氨基吡啶并[4,3-d]嘧啶的合成。这些化合物被证明是表皮生长因子受体(EGFR)酪氨酸激酶活性的一类新型抑制剂。使用一系列主要因其广泛电子性质而选择的取代基(NO2、Br、CF3、OMe、NH2和NMe2),确定了4-(苯氨基)-和4- [(苯甲基)氨基]侧链取代的构效关系(SARs)。在苯氨基系列中,3-取代衍生物比相应的2-和4-取代类似物更有效。对于3-取代的化合物,吸电子有利于活性,这种关系可以量化,3-Br是最有效的化合物(IC50 = 0.01 microM,而未取代侧链衍生物的IC50 = 0.34 microM)。对于2-或4-取代基,没有明显的这种相关性,尽管Br仍然是最佳取代基。相比之下,在4- [(苯甲基)氨基]系列中,侧链取代并无益处。对于4-(苯氨基)系列,取代基SARs与先前在4-(苯氨基)喹唑啉中发现的大致相似。这些结果表明,在一系列不同的发色团中,侧链SARs可能大致不变,用于优化EGFR抑制活性的首选侧链是4- [(3-溴苯基)氨基]。